STIM Neuronetics

Journal of Affective Disorders Publishes Clinical Data Suggesting NeuroStar® Advanced Therapy as a First-line Treatment for Major Depressive Disorder

Journal of Affective Disorders Publishes Clinical Data Suggesting NeuroStar® Advanced Therapy as a First-line Treatment for Major Depressive Disorder
EN
13/10/2020

Underlying

STIMNeuronetics

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Neuronetics

 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics Reports Third Quarter 2025 Financial and Operating Results...

Neuronetics Reports Third Quarter 2025 Financial and Operating Results and Announces CEO Transition Plan Delivered $37.3 million total revenue in Q3 2025, representing 11% adjusted pro forma revenue growth versus Q3 2024 Generated Greenbrook clinic revenue of $21.8 million in Q3 2025, an increase of 25% on an adjusted pro forma basis versus Q3 2024 Continued cash management improvement, with cash used in operations of $0.8 million in Q3 2025 Strengthened balance sheet in Q3 2025, ending the quarter with $34.5 million of total cash, consisting of cash, cash equivalents, and restrict...

November 4, 2025 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)...

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced the granting of inducement awards to twelve new employees as described below. In accordance with NASDAQ Listing Rule 5635(c)(4), these awards were approved by Neuronetics’ Compensation Committee and made as a material inducement to the...

October 31, 2025 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA ...

Neuronetics Announces Three-Year Exclusive Partnership with Elite DNA Behavioral Health to Expand NeuroStar Access and Operational Excellence New collaboration provides services to streamline patient support, reduce administrative burden, and expand access to advanced TMS treatment across Elite DNA Clinics MALVERN, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced an exclusive thr...

October 30, 2025 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

Neuronetics to Report Third Quarter 2025 Financial and Operating Resul...

Neuronetics to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call MALVERN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, the leading provider of Transcranial Magnetic Simulation (TMS), announced that it plans to release third quarter 2025 financial and operating results prior to market open on Tuesday, November 4, 2025...

October 21, 2025 1 EN
 PRESS RELEASE
Free
STIM NEURONETICS

New York State Medicaid Expands Coverage for TMS Therapy, Including Ne...

New York State Medicaid Expands Coverage for TMS Therapy, Including NeuroStar® Advanced Therapy, to Treat Major Depressive Disorder (MDD) Over 5 million New York Medicaid members to gain access to Transcranial Magnetic Stimulation (TMS) services MALVERN, Pa., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar® Advanced Therapy, the leading provider of Transcranial Magnetic Si...

September 17, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch